The tradipitant saga stretches back to September 2024, when the FDA declined to approve Vanda’s drug in gastroparesis, a ...

Vanda Pharmaceuticals emphasized its strategic ... s 2025 revenue guidance reflects confidence in scaling its existing products, while its 2030 targets highlight a long-term growth vision.

Vanda Pharmaceuticals is suing the FDA again, this time alleging the agency is unlawfully delaying a hearing to discuss the ...

UK group Cycle Pharma has made an unsolicited ... The potential sales revenue growth from those products is likely part of the interest in Vanda, along with the prospects for pipeline drugs.

Vanda Pharmaceuticals Inc. (NASDAQ ... VNDA has three approved products. The first product is HETLIOZ ® (tasimelteon), a melatonin receptor agonist, whose capsules are used to treat Non-24 ...

Vanda Pharmaceuticals (VNDA) stated that “FDA bureaucrats have committed to delay Vanda’s request for a hearing on the approvability of ...

Vanda Pharmaceuticals has a 12-month low of $ ... The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of ...

After years of back-and-forth with the FDA over Hetlioz's potential use as a jet lag disorder treatment, Vanda Pharmaceuticals ... safety and efficacy of their products, patients ultimately ...

For more information on the AAN Annual Meeting, please refer to www.aan.com. About Vanda Pharmaceuticals Inc. Vanda is a leading global biopharmaceutical company focused on the development and ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.